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The mechanisms of homing of endothelial progenitor cells (EPCs) to sites of ischemia are 
unclear. Here, we demonstrate that ex vivo–expanded EPCs as well as murine hematopoietic 
Sca-1
 
 
 
/Lin
 
 
 
 progenitor cells express 
 
 
 
2-integrins, which mediate the adhesion of EPCs to 
endothelial cell monolayers and their chemokine-induced transendothelial migration in 
vitro. In a murine model of hind limb ischemia, Sca-1
 
 
 
/Lin
 
 
 
 hematopoietic progenitor cells 
from 
 
 
 
2-integrin–deficient mice are less capable of homing to sites of ischemia and of 
improving neovascularization. Preactivation of the 
 
 
 
2-integrins expressed on EPCs by 
activating antibodies augments the EPC-induced neovascularization in vivo. These results 
provide evidence for a novel function of 
 
 
 
2-integrins in postnatal vasculogenesis.
 
The term vasculogenesis was originally intro-
duced to describe the de novo formation of
new vessels from angioblasts during embryonic
development (1). Accumulating evidence sug-
gests that vasculogenesis, mediated by circulat-
ing bone marrow–derived endothelial progenitor
or hematopoietic stem cells, plays an important
role in postnatal neovascularization of adult
ischemic tissues (2–7). Human endothelial pro-
genitor cells (EPCs) were initially characterized
by the expression of the VEGF receptor 2
(VEGF R2; Flk-1) and a hematopoietic marker
such as CD133 (6). EPCs are mobilized from
the bone marrow during ischemia (8, 9) or ex-
ogenously by stimulation with cytokines such
as VEGF and contribute to neovascularization
of ischemic tissues (4, 8, 10) or tumors (11).
Infusion of EPCs or isolated hematopoietic
progenitor cells (e.g., murine Sca-1
 
 
 
/Lin
 
 
 
cells) augmented neovascularization of ischemic
myocardium and limbs and improved left
ventricular function after myocardial ischemia
(12–15). EPCs are preferentially recruited to
sites of ischemia and incorporated into vascular
structures (2, 4, 8, 12, 16). The mechanisms of
EPC homing to sites of ischemia are still unclear.
Because integrins are mediating the homing of
transplanted hematopoietic stem cells to the
bone marrow (17) as well as the recruitment of
inflammatory cells to sites of inflammation,
we investigated the contribution of integrins
and especially of 
 
 
 
2-integrins for homing and
neovascularization capacity of EPCs and he-
matopoietic stem cells to areas of ischemia.
Recruitment of inflammatory cells requires
a coordinated sequence of multistep adhesive
and signaling events, including selectin-mediated
rolling, leukocyte activation by chemokines,
integrin-mediated firm adhesion and diapedesis
(18–22). During firm adhesion of leukocytes
to the endothelium, members of the 
 
 
 
2-integrin
family, LFA-1 (
 
 
 
L
 
 
 
2, CD11a/CD18), Mac-1
(
 
 
 
M
 
 
 
2, CD11b/CD18), and p150,95 (
 
 
 
X
 
 
 
2,
CD11c/CD18), as well as 
 
 
 
1-integrins on
leukocytes interact with endothelial counterli-
gands such as ICAM-1, VCAM-1, and sur-
face-associated fibrinogen. Mac-1 also regulates
leukocyte adhesion to provisional matrix sub-
strates including fibrinogen, which is deposited
at sites of inflammation and injury upon in-
creased vascular permeability and damage (19,
20, 23). Because 
 
 
 
2-integrins are strongly
expressed on EPCs, we studied the role of
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the 
 
 
 
2-integrins for homing and neovascularization capacity
of peripheral blood–derived cultivated human EPCs, bone
marrow–derived murine hematopoietic Sca-1
 
 
 
/Lin
 
 
 
 as well
as VEGF R2
 
 
 
/Lin
 
 
 
 progenitor cells. Our results show that
 
 
 
2-integrins mediate the adhesive interactions of EPCs to
mature endothelial cells and to extracellular matrix proteins
and are critical for chemokine-induced transendothelial mi-
gration of EPCs in vitro. In a mouse model of hind limb
ischemia, using murine Sca-1
 
 
 
/Lin
 
 
 
 hematopoietic progen-
itor cells from 
 
 
 
2-integrin–deficient (
 
 
 
2
 
   
 
) mice, we dem-
onstrate that 
 
 
 
2-integrins are involved in the homing of he-
matopoietic progenitor cells to sites of ischemia and are
critical for their neovascularization capacity. Alternately, pre-
activation of the 
 
 
 
2-integrins on EPCs by activating anti-
bodies significantly augments the in vivo neovascularization
capacity of EPCs, indicating a new therapeutic approach to
promote homing of EPCs.
 
RESULTS
EPCs express active 
 
 
 
2-integrins
 
To characterize the expression of adhesion receptors on
EPCs, we used a microarray assay comparing EPCs and hu-
man umbilical vein endothelial cells (HUVECs). The endo-
thelial phenotype of the ex vivo–cultivated EPCs was con-
firmed by immunostaining, FACS analysis, and functional
response to shear stress as described previously (12, 24, 25).
Strikingly, EPCs expressed mRNA for the 
 
 
 
2-integrin sub-
unit and for the corresponding CD11a, CD11b, and CD11c
subunits, whereas mature endothelial cells showed only a
very low mRNA expression of the 
 
 
 
2-integrins (Fig. 1 A).
FACS analysis confirmed the surface expression of the 
 
 
 
2-
integrin (CD18) and the CD11a, CD11b, and CD11c sub-
units (Fig. 1 B). Coexpression of the endothelial markers
von Willebrand factor (vWF) and CD31 on 
 
 
 
2-integrin
positive EPCs was demonstrated by FACS analysis (Fig. 1 B
and not depicted). mRNA expression of eNOS and VE-
cadherin confirmed the endothelial phenotype of the EPCs
(Fig. 1 C and not depicted). In contrast with EPCs, mature
endothelial cells (HUVECs) do not express the 
 
 
 
2-integrin
subunit (CD18) on the cell surface (unpublished data).
Because 
 
 
 
2-integrins undergo a conformational activa-
tion in the presence of divalent cations, such as Mn
 
2
 
 
 
 (26),
we investigated whether Mn
 
2
 
 
 
 is capable of activating 
 
 
 
2-
integrins on the surface of EPCs. For this purpose, we de-
tected activated 
 
 
 
2-integrins by using specific antibodies,
which recognize activation-dependent epitopes of the CD11a
(mAb24) and CD11b (CBRM1/5) subunits (27, 28). Al-
though the stimulation of EPCs with Mn
 
2
 
 
 
 had no effect on
the total protein expression of CD11a or CD11b subunits,
it enhanced the expression of the activation-dependent
epitopes on the CD11a and CD11b subunits (Fig. 2 A).
These results demonstrate that EPCs express functionally ac-
tive 
 
 
 
2-integrins on their surface.
 
 
 
2-integrins mediate adhesion of EPCs on endothelial cell 
monolayers and extracellular matrix proteins
 
To assess the functional capacity of 
 
 
 
2-integrins expressed
by EPCs, we investigated their role in the adhesion of EPCs
on mature endothelial cell monolayers (HUVECs) and on
recombinant human ICAM-1 and fibrinogen in a static ad-
hesion assay. Stimulation of EPCs with Mn
 
2
 
 
 
 significantly
increased the adhesion of EPCs to TNF-
 
 
 
–prestimulated
HUVECs. Addition of an inhibitory 
 
 
 
2-integrin antibody
significantly blocked EPC adhesion to HUVECs (Fig. 2 B).
VLA–4 as well as 
 
 
 
V
 
 
 
3-integrin can also mediate intercellu-
lar adhesive interactions by binding to VCAM-1 and PE-
CAM-1, respectively (23, 29). Therefore, a synthetic VLA-4
inhibitor and a cyclic RGD peptide (established inhibitor of
the 
 
 
 
V
 
 
 
3- and 
 
 
 
V
 
 
 
5-integrin) were engaged in these stud-
ies. However, these inhibitors did not significantly inhibit
EPC adhesion to HUVECs (Fig. 2 B). An inhibitory VLA-4
antibody (clone HP2/1), as well as an inhibitory 
 
 
 
1-integrin
antibody (clone 6S6), also had no effect on the adhesion of
EPCs to HUVECs (unpublished data). These results demon-
Figure 1. Expression of  2-integrins in human EPCs. (A) mRNA ex-
pression profile of integrins in EPCs and HUVECs was assessed by microarray 
(n   3 each). *, P   0.05 versus HUVECs. (B) FACS analysis of EPCs. FL1-H: 
vWF; FL2-H: integrins (n   3 each). (C) mRNA expression of eNOS and 
GAPDH was assessed in EPCs from three different donors. 
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strate that EPC adhesion to endothelial cells is predomi-
nantly mediated by 
 
 
 
2-integrins expressed on EPCs.
Endothelial ICAM-1 and extracellular matrix-associated
fibrinogen are established ligands for the 
 
 
 
2-integrins (30–
33). Therefore, we investigated whether EPCs are capable of
binding to immobilized recombinant human ICAM-1 and
fibrinogen via 
 
 
 
2-integrins. Indeed, stimulation with either
Mn
 
2
 
 
 
 or an activating 
 
 
 
2-integrin antibody (KIM185) in-
duced adhesion of EPCs to immobilized human ICAM-1
and fibrinogen (Fig. 2, C and D). Adhesion induced by both
stimuli was completely abolished in the presence of an inhib-
itory 
 
 
 
2-integrin antibody (Fig. 2, C and D). In contrast, an
inhibitory 
 
 
 
1-integrin antibody had no effect on the adhe-
sion of EPCs to human ICAM-1 (unpublished data). These
results demonstrate that EPCs bind to fibrinogen and endo-
thelial ICAM-1 in a 
 
 
 
2-integrin–dependent manner.
 
Role of 
 
 
 
2-integrins for transmigration of EPCs
 
We investigated the involvement of 
 
 
 
2-integrins in the transen-
dothelial migration of EPCs in a transwell transmigration assay.
Chemoattraction of EPCs by MCP-1, SDF-1
 
 
 
, and VEGF sig-
nificantly increased the transmigration rate of EPCs through
HUVEC monolayers (Fig. 3). Addition of an inhibitory 
 
 
 
2-
integrin antibody (anti-CD18) significantly reduced EPC trans-
migration, whereas an inhibitory 
 
 
 
1-integrin antibody (anti-
CD29) and RGD peptides had no effect (Fig. 3). Moreover, an
inhibitory VLA-4 antibody did not affect chemokine-induced
transendothelial migration of EPCs (unpublished data). Thus,
 
 
 
2-integrins, but not 
 
 
 
1-integrins, mediate chemokine and
VEGF-induced transendothelial migration of EPCs (Fig. 3).
 
Role of 
 
 
 
2-integrins for neovascularization after ischemia
 
Next, we determined whether 
 
 
 
2
 
   
 
 mice have an impaired
neovascularization capacity. Hind limb ischemia was induced
in WT and 
 
 
 
2
 
   
 
 mice. Perfusion was assessed 14 d after in-
duction of ischemia by laser Doppler imaging.  2    mice
showed a significantly impaired recovery in limb perfusion as
compared with WT controls (Fig. 4, A and B), suggesting that
 2-integrins contribute to neovascularization after ischemia.
Role of  2-integrins for the in vivo homing and 
neovascularization capacity of Sca-1 /Lin  bone marrow cells
To assess the in vivo relevance of  2-integrins for progeni-
tor cell homing to sites of ischemia and progenitor cell–
Figure 2. Integrins and EPC adhesion. (A) EPCs were activated with 2 mM 
MnCl2 for 30 min. Activation of integrins was determined by CBRM1/5 and 
mAb24 antibodies (left) and expression of CD11a and CD11b was con-
trolled by FACS analysis (right; n   3). (B) Adhesion of EPCs to 10 ng/ml 
TNF- –prestimulated HUVECs was stimulated where indicated with 
MnCl2. 105 EPCs/well (in 100  l adhesion buffer) were added to the HUVEC 
monolayers in the absence or presence of 30  g/ml of blocking monoclonal 
anti– 2-integrin antibodies (clone IB4 or mAb 60.3), 30  g/ml of murine 
isotype control antibodies, 50  M of the inhibitory agents cyclic RGD pep-
tide or 50  M of VLA-4-inhibitor. The total number of EPCs added to the 
well is set as 100%. *, P   0.01 versus MnCl2   isotype antibody; #, P   0.01 
versus isotype control. (C and D) EPCs were treated with 2 mM MnCl2 or 
10  g/ml  2-integrin–activating antibody. Adhesion to fibrinogen- or 
ICAM-1–coated plates was detected after 20 min in the presence or absence 
of  2-integrin–inhibitory antibody or isotype control antibodies (n   4). *, 
P   0.05 versus MnCl2   isotype IgG; #, P   0.05 versus activating anti- 2   
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induced neovascularization, we used bone marrow–derived
stem/progenitor cells in a mouse model of hind limb ische-
mia. First, we detected the expression of CD18 on periph-
eral blood Sca-1 /c-kit  cells. The  2-integrin subunit
CD18 was expressed on  95% of the Sca-1 /c-kit  cells
(Fig. 5 A). Peripheral blood cells from  2    mice were
used as negative control. As expected, no CD18 staining
was detectable (Fig. 5 A). Second, we isolated Sca-1 /Lin 
progenitor cells from the bone marrow of wild-type mice
by magnetic beads and detected the expression of  2-inte-
grin by FACS analysis. The majority of isolated Sca-1 /
Lin  cells (98.5   0.2%) expressed the CD18 surface anti-
gen. Moreover, adhesion of murine bone marrow Lin 
progenitor cells to TNF- –pretreated mature endothelial
cells was significantly blocked by  2-blocking antibodies
(unpublished data).
The functional activity of the stem/progenitor cells to
improve neovascularization was assessed by intravenous infu-
sion of Sca-1 /Lin  bone marrow cells derived from either
wild-type or  2    mice into athymic mice 24 h after induc-
tion of limb ischemia. After 14 d, transplantation of Sca-1 /
Lin  bone marrow cells from wild-type mice significantly
enhanced the recovery of blood flow of the ischemic hind
limbs of athymic mice as compared with ischemic hind limbs
from untreated athymic mice (Fig. 5 B). In contrast,  2   
Sca-1 /Lin  bone marrow cells were significantly less effec-
tive for improving recovery of limb perfusion as compared
with wild-type Sca-1 /Lin  bone marrow cells (Fig. 5 B).
Moreover, histological evaluation of ischemic hind limbs
of athymic mice 14 d after cell infusion revealed a signifi-
cantly lower capillary density in mice receiving  2    Sca-
1 /Lin  bone marrow cells compared with mice receiving
wild-type cells (Fig. 5 C). Furthermore, the number of in-
corporated male Sca-1 /Lin  cells in female recipients was
determined by fluorescence in situ hybridization for the mu-
rine Y-chromosome of the infused male cells. The number
of incorporated Y-chromosome positive cells was signifi-
Figure 3.  2-Integrins mediate the chemokine-induced transendothe-
lial migration of EPCs. Transendothelial migration of EPCs was stimu-
lated where indicated with 50 ng/ml MCP-1, 100 ng/ml SDF-1, or 50 ng/ml 
VEGF for 18 h. EPCs transmigrated in the presence or absence of indicated 
blocking antibodies or isotype control antibodies (30  g/ml each) or 10  g/ml 
RGD peptides. Data of a typical experiment (triplicates) are presented. Similar 
results were obtained in at least three separate experiments. *, P   0.05 
versus MCP-1, SDF-1, or VEGF   isotype control IgG.
Figure 4. Neovascularization of WT versus CD18    mice after hind 
limb ischemia. 14 d after induction of hind limb ischemia, perfusion of 
the ischemic limb was determined by laser Doppler imaging. Quantification 
(n   6 per group) (A) and representative images (B). Arrows indicate isch-
emic linbs.JEM VOL. 201, January 3, 2005 67
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cantly lower for the infusion of  2    cells as compared with
the infusion of wild-type cells (Fig. 5, D and E).
Similar results were obtained when using isolated VEGF
R2 /Lin  bone marrow–derived cells. The majority of
VEGF R2 /Lin  cells expressed CD18 (89   9.6%).
Moreover, VEGF R2 /Lin  cells derived from CD18   
mice cells showed a significantly reduced capacity to aug-
ment blood flow after ischemia as compared with WT cells
(WT 180   15% of untreated control mice; CD18    cells:
125   7% of untreated control mice). These results indicate
that the  2-integrins are involved in the homing of pro-
genitor cells to ischemic tissues and their neovascularization
capacity.
Activation of the  2-integrins improves in vivo homing and 
neovascularization capacity of EPCs
Because  2-integrins are involved in the homing of EPCs, we
investigated whether preactivation of  2-integrins may im-
prove homing and neovascularization capacity of human
EPCs in the mouse model of hind limb ischemia. Ex vivo–
expanded human EPCs isolated from peripheral blood were
pretreated with the  2-integrin–activating antibody (KIM
185), which was shown before to enhance  2-integrin–
dependent adhesion of EPCs to endothelial ICAM-1 or fi-
brinogen (Fig. 2), and were subsequently infused into athymic
mice. To be able to detect an increase in progenitor cell–medi-
ated neovascularization, we used a reduced number of EPCs
Figure 5. Role of  2-integrins for in vivo homing of Sca-1 /Lin  
stem/progenitor cells and neovascularization capacity. (A) Peripheral 
blood was gated on the lymphocyte/monocyte fraction (R1) and stained 
for Sca-1–FITC (FL1) and c-Kit–allophycocyanin (APC; FL4). Gate R2 defines 
cells, which are Sca-1 c-Kit . Cells detected in both R1 and R2 are ana-
lyzed for expression of CD18-PE (FL2). Expression of CD18 in Sca-1 /c-Kit  
cells was deficient in CD18    mice. A representative FACS analysis is 
shown. (B and C) A total of 105 male Sca-1 /Lin  cells were isolated from 
bone marrow and infused intravenously into female nude mice 24 h after 
induction of hind limb ischemia. Laser Doppler-derived blood flow (arrows 
indicate ischemic limbs) (B) and capillary density (C) was determined after 
2 wk (n   5 per group). (D and E) Incorporation of Y-chromosome positive 
injected murine Sca-1 /Lin  cells isolated from male wild-type or CD18    
mice in female recipients after hind limb ischemia (n   4 per group; n   10 
images per mouse were analyzed). Representative images (E) stained for 
the panendothelial marker MECA-32 (FITC, green), nuclei (Sytox; blue), 
and Y-chromosome (Cy3-labeled murine probe, red). Arrows indicate
Y-chromosome positive cells.PROGENITOR CELL HOMING AND NEOVASCULARIZATION | Chavakis et al. 68
(105 cells), which is lower than previously published numbers
(5   105 EPCs; reference 25), to yield a 50% improvement of
neovascularization as compared with untreated mice.
Preincubation of the EPCs with the activating  2-inte-
grin antibody resulted in a significantly enhanced neovascu-
larization capacity of infused EPCs in comparison with
control antibody-treated EPCs as assessed by laser Doppler
imaging (Fig. 6 A). Incorporation of human EPCs was de-
tected by confocal microscopy using antibodies directed
against human HLA and the endothelial marker protein
vWF (Fig. 6, B–D). Incorporation of  2-activating anti-
body-treated EPCs into the ischemic muscle was increased
in comparison with control antibody-treated EPCs (Fig. 6, B
and C). Moreover, the numbers of capillaries and small arte-
rioles (20–50  m) were significantly augmented in mice
treated with preactivated EPCs (Fig. 6, E and F; capillary
Figure 6. Activation of  2-integrins improves in vivo homing and 
neovascularization capacity of EPCs. (A) EPCs were pretreated with  2-
integrin–activating antibody or isotype control antibody (20  g/ml each) 
for 30 min, and 105 cells were injected intravenously in nude mice 24 h after 
induction of hind limb ischemia. Perfusion was determined by laser Doppler 
imaging after 2 wk (n   6 per group). (B–D) Incorporation of human EPCs 
(stained for HLA-ABC; Alexa 555, red) into vessels (endothelial marker 
CD31-FITC, green) after pretreatment with isotype control antibody or ac-
tivating  2-integrin antibody. Double positive cells were quantified (B) and 
representative overviews (C) and high power images (D) are shown from 
10 sections provided by five mice per group. (E and F) Conductance vessels 
were identified by staining for smooth muscle  -actin using a Cy3-labeled 
mouse monoclonal antibody (red). The number of small (20–50  m), medium 
( 50–100  m), and large vessels ( 100  m) was counted separately. 
Data are mean   SEM (n   5). (A, B, and E) *, P   0.05 versus no cells; 
**, P   0.05 versus isotype Ab-treated EPCs.JEM VOL. 201, January 3, 2005 69
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density: EPC   control mAb: 0.77   0.10 capillaries per
myocyte; EPC   activating mAb: 1.32   0.09; P   0.003).
Thus, an external activation of the  2-integrins by an acti-
vating antibody before infusion is capable of improving the
neovascularization capacity of EPCs.
DISCUSSION
The data of the present paper underscore the importance of
 2-integrins for the proangiogenic activity of EPCs and
bone marrow–derived progenitor cells. Specifically, our in-
vestigations revealed the following: (a) EPCs as well as he-
matopoietic stem/progenitor cells express  2-integrins; (b)
 2-integrins expressed on EPCs can be activated by Mn2 
and can mediate the adhesion of EPCs to mature endothelial
cells, to recombinant human ICAM-1, and to fibrinogen
and the chemokine-induced transendothelial migration of
EPCs; (c)  2    animals display a neovascularization defect
in the model of hind limb ischemia; (d)  2-integrins are in-
volved in the in vivo homing of progenitor cells to sites of
ischemia and their vascular integration and significantly con-
tributed to the neovascularization capacity of infused bone
marrow Sca-1 /Lin  or VEGF R2 /Lin  progenitor cells
in the mouse model of hind limb ischemia as demonstrated
using the  2    progenitor cell populations; (e) stimulation
of ex vivo–expanded human EPCs by preincubation with an
activating   2-integrin antibody significantly enhanced the
homing of EPCs to sites of ischemia and EPC-induced
neovascularization. Therefore, the present paper unravels a
novel function of the  2-integrin subunit CD18 for neovas-
cularization exceeding its well-known function in innate and
adaptive immune responses.
Increasing evidence suggests that  2-integrins are not
only expressed on differentiated leukocytes but also on he-
matopoietic stem/progenitor cells (34, 35). Our in vitro data
suggest that  2-integrins expressed on EPCs mediate hom-
ing functions such as endothelial adhesion and transmi-
gration. Moreover,  2-integrins contribute to the in vivo
homing of bone marrow–derived progenitor cells to ische-
mic tissue. In line with these data, it has been reported pre-
viously that  2-integrins mediate adhesion and transmigra-
tion of hematopoietic stem/progenitor cells (36–38). In a
recent paper assessing in vivo homing of embryonic EPCs
derived from cord blood, the circulating cells arrested within
tumor microvessels extravasated into the interstitium and in-
corporated into neovessels, suggesting that adhesion and
transmigration are involved in the recruitment of EPCs to
sites of tumor angiogenesis (39). Thus, it is conceivable to
speculate that ex vivo–expanded adult EPCs and hemato-
poietic stem/progenitor cells may engage similar pathways
for recruitment to sites of ischemia and incorporation into
newly forming vessels.
Our in vivo data provide the first evidence for a direct
participation of  2-integrins in neovascularization processes
and particularly in stem/progenitor cell–mediated, ischemia-
induced vasculogenesis. Adamis and colleagues previously
highlighted the role of  2-integrins for corneal and choroi-
dal angiogenesis induced by injury (40, 41). In both studies,
 2    mice displayed a reduced inflammation-associated an-
giogenic response after injury and these effects were associ-
ated with reduced inflammatory cell infiltrates (40, 41). Yet,
no incorporation of leukocytes into new vessels was reported
in these studies. Moreover, the same group demonstrated
that, in the case of retinal ischemia, leukocyte–endothelial
cell interactions contribute to the development of ischemia
by inducing vascular obliteration via Fas ligand–mediated
endothelial cell apoptosis (42). In contrast with these find-
ings, our data provide evidence that, during hind limb ische-
mia, intravenous infusion of bone marrow hematopoietic
progenitor cells leads to incorporation of the transplanted
cells in newly formed vessels and to improvement of neovas-
cularization in an at least partially  2-integrin–dependent
manner. As opposed to EPCs, infusion of inflammatory cells,
such as monocytes/macrophages, had only a slight if any ef-
fect on the neovascularization of ischemic limbs in the
model of hind limb ischemia in athymic mice (25). Thus,
our results support a novel direct function of  2-integrins
in progenitor cell–induced vasculogenesis during ischemia,
which is distinct from the indirect role of  2-integrins in the
inflammation-associated angiogenesis described by Adamis
and colleagues (40, 41). Because the  2    mice display no
defect in the mobilization of progenitor cells (43), the neo-
vascularization defect in the  2    mice in the model of
hind limb ischemia is most conceivably mediated by a hom-
ing defect of progenitor cells into ischemic tissue.
Interestingly, our present data indicate that the recruit-
ment of hematopoietic progenitor cells to sites of ischemia is
mediated at least in part by different mechanisms compared
with the homing of infused cells into the bone marrow of le-
thally irradiated recipient mice, which is predominantly me-
diated via  4 1 (17, 43). In this context,  2-integrins only
act in a synergistic manner together with the  4 1-integrin.
Our finding that  2-integrin deficiency does not completely
block homing and neovascularization improvement after in-
fusion of Sca-1 /Lin  bone marrow cells suggests that other
mechanisms may additionally be involved in these processes.
We cannot exclude that  4 1-integrin partially compensates
for the lack of  2-integrin during in vivo homing of Sca-1 /
Lin  bone marrow cells. Interestingly, the homing of inflam-
matory cells during pneumonia or myocardial ischemia in
 2    mice is mediated by the  4 1-integrin (44, 45).
Moreover, the initial cell arrest of embryonic progenitor cell
homing during tumor angiogenesis was suggested to be
mediated by E- and P-selectin and P-selectin glycoprotein
ligand-1 (39). Yet, it is important to underscore that this
work was performed with embryonic EPCs, whereas we
used adult EPCs and bone marrow stem/progenitor cells. It is
likely that different cell types may use distinct mechanisms for
homing to sites of ischemia. In addition, it is well established
that interactions of selectins with selectin–ligands mediate the
rolling of cells on the surface of endothelial cells as the initial
step of homing (21). Further studies are needed to elucidate a
potentially synergistic role of other adhesion molecules andPROGENITOR CELL HOMING AND NEOVASCULARIZATION | Chavakis et al. 70
their counterligands for the multistep recruitment process of
adult endothelial progenitor and stem cells to ischemic tissue.
Regardless of potentially additive mechanisms involved
in the recruitment of stem/progenitor cells to areas of ische-
mia, our data clearly demonstrate that preincubation of
EPCs with a  2-integrin–activating antibody markedly en-
hanced the incorporation of transplanted EPCs in vessels
and the neovascularization of ischemic limbs. The peripheral
blood–derived EPCs used in the present paper are already
used in clinical trials to improve neovascularization in pa-
tients with ischemic heart diseases (15). Thus, our results
could have important clinical implications as they disclose a
mechanism to enhance homing of EPCs and, thereby, im-
prove neovascularization capacity of infused EPCs.
In summary, the present paper demonstrates for the first
time a critical role of  2-integrins in vitro and in vivo for
homing and neovascularization capacity of endothelial pro-
genitor and hematopoietic progenitor cells. Moreover, our
results show that activation of  2-integrins appears to be a
feasible and promising tool to improve the efficacy of EPC-
induced neovascularization. A better understanding of the
homing mechanisms of EPCs may lead to the development
of new therapeutic strategies for improvement of vasculo-
genesis in patients with ischemic diseases.
MATERIALS AND METHODS
Cell culture
Mononuclear cells (MNCs) were isolated by density–gradient centrifuga-
tion with Ficoll from peripheral blood of healthy human volunteers as de-
scribed previously (46). Immediately after isolation, total MNCs (8   106
cells/ml medium; cell density 2.5   106 cells/cm2) were plated on culture
dishes coated with 10  g/ml human fibronectin (Sigma-Aldrich) and
maintained in endothelial basal medium (Cambrex) supplemented with 1
 g/ml hydrocortisone, 12  g/ml bovine brain extract, 50  g/ml genta-
mycin, 50 ng/ml amphotericin B, 10 ng/ml epidermal growth factor, and
20% FCS. After 3 d, nonadherent cells were removed, and adherent cells
were incubated in medium for another 24 h before initiation of the exper-
iments. EPCs were characterized by dual staining for 1,1 –dioctadecyl–
3,3 ,3 –tetramethylindo-carbocyanine–labeled acetyl low-density lipopro-
tein, lectin, and expression of endothelial markers KDR, VE-cadherin, and
vWF (25).
Sca-1 /Lin  cells were purified from BM MNCs from wild-type and
CD18    mice by negative selection using a cocktail of biotinylated anti-
bodies to lineage markers (Lineage cell depletion kit, mouse; Miltenyi Bio-
tec) for 10 min at 4 C followed by antibiotin microbeads for 15 min (Mil-
tenyi Biotec). The Lin  BM cells were incubated with anti–Sca-1 microbeads
(Miltenyi Biotec) for 15 min and Sca-1 /Lin  BM cells were collected (7).
To obtain VEGFR2  Lin  cells, Lin  cells were incubated with biotinyl-
ated Flk-1 antibodies (DSB-X biotin protein labeling kit; Molecular Probes;
antibody was obtained from BD Biosciences) for 30 min at 4 C followed by
antibiotin microbeads for 15 min.
HUVECs were purchased from Cambrex and cultured in endothelial
basal medium supplemented with 1  g/ml hydrocortisone, 12  g/ml bo-
vine brain extract, 50  g/ml gentamycin, 50 ng/ml amphotericin-B, 10
ng/ml epidermal growth factor, and 10% FCS until the third passage. After
detachment with trypsin, cells (4   105 cells) were grown in 6-cm cell cul-
ture dishes or 96-well plates for at least 18 h as described previously (47).
Oligonucleotide microarrays, FACS
10  g of total RNA was hybridized to the HG-U95Av2 microarray (9670
human genes; Affymetrix, Inc.). The standard protocol used for sample
preparation and microarray processing is available from Affymetrix, Inc. Ex-
pression data were analyzed using Microarray Suite version 5.0 (Affymetrix,
Inc.) and GeneSpring version 4.2 (Silicon Genetics). 3   105 human EPCs,
peripheral blood, or isolated Sca-1 /Lin  cells were incubated for 30 min at
4 C with FITC- or PE-labeled antibodies (anti-CD11a, -CD11b, -CD11c,
-CD18, –Sca-1, and –c-kit; BD Biosciences; anti-vWF was obtained from
Acris) or CBRM1/5-antibody (BD Biosciences) for 30 min at 37 C. The
mAb24 antibody (provided by N. Hogg, Cancer Research UK London
Research Institute, London, England, UK) was incubated for 30 min at 4 C
and detected with a secondary FITC-labeled goat anti–mouse antibody
(DakoCytomation). Surface expression was quantified using a FACS Cali-
bur (BD Biosciences).
Adhesion, transmigration experiments
Cell–cell adhesion. Cell–cell adhesion was performed as described previ-
ously (48, 49). Confluent HUVEC monolayers were stimulated with TNF- 
(Sigma-Aldrich) for 24 h. Ex vivo–expanded EPCs were stained with
Cell Tracker green-CMFDA (Molecular Probes) and were resolved in ad-
hesion buffer (150 mM NaCl, 20 mM Hepes, 2 mM MgCl2, 0.05% BSA,
pH 7.4). A total of 105 EPCs/well (in 100  l adhesion buffer) was added to
the HUVEC monolayers in the absence or presence of blocking monoclo-
nal  2-integrin antibodies (clone IB4; Qbiogene; or mAb 60.3; J. Harlan,
University of Washington, Seattle, WA), murine isotype control antibodies
(Qbiogene), inhibitory agents cyclic RGD peptide or VLA-4 inhibitor
(4-[{2-methyl-phenyl}aminocarbonyl]aminophenyl)acetyl-fibronectin-CS-1
fragment (1980–1983). After 20 min of incubation (37 C), the plates were
washed twice with adhesion buffer at room temperature to remove nonad-
herent cells. Adherent cell tracker green-labeled EPCs were quantified in
triplicates on a fluorescence plate reader (Fluostat; BMG Lab Technologies).
Cell–matrix adhesion. Cell–matrix adhesion was performed as described
previously (48, 49). 96-well plates were coated overnight (4 C) with 10
 g/ml human fibrinogen (Enzyme Research Laboratories) or soluble re-
combinant human ICAM-1 (Bender MedSystems) and blocked with 1%
(wt/vol) BSA for 1 h at room temperature. Ex vivo–expanded human
EPCs in adhesion buffer were seeded at 1.2   105 cells/well in 100  l in
the absence or presence of 2 mM MnCl2 or activating human  2-integrin
antibody (clone KIM185; M. Robinson, Celltech Ltd., Slough, England,
UK) and were incubated with blocking  2-integrin mAb (clone IB4 or
mAb 60.3) or murine isotype control antibodies (Qbiogene) for 20 min at
37 C. After removal of nonadherent cells by two washing steps, adhesion
was quantified in triplicates by counting adherent cells in five randomly se-
lected fields per well (magnification, 20; Axiovert 100; Carl Zeiss Micro-
Imaging, Inc.).
Transmigration. Transendothelial migration was performed as described
previously (50) using 6.5-mm transwell filters with 8- m pore size (Costar).
After inserts were coated with 0.2% gelatin (Sigma-Aldrich), HUVECs
were seeded on transwell filters and cultivated for 48 h before the experi-
ments were performed in a humidified atmosphere (37 C, 5% CO2). At the
beginning of the experiment, 600  l of migration assay medium (serum-
free RPMI 1640 in the absence or presence of MCP-1, SDF1 , or VEGF;
R&D Systems) was added to the lower compartment of the transwell sys-
tem. EPCs (5   105 in 100  L) were added to the top compartment in the
presence or absence of 30  g/ml of blocking anti– 2-integrin antibody
(mAb 60.3), anti– 1-integrin antibody (clone 6S6; Chemicon), anti– 4-inte-
grin antibody (clone HP2.1; Immunotech), murine isotype control antibod-
ies (Qbiogene), or RGD peptides. After 18 h at 37 C, the number of cells
transmigrated to the bottom compartment was quantified in duplicates with
a cell counter (CASY-Counter; Schärfe-System). All inserts were fixed and
stained to confirm the confluence of the endothelial monolayer.
Animal experiments
Mice.  8-wk-old  2    mice and their age-matched wild-type littermates
(either 129/Sv or C57BL/6J) were generated as described previously (51).JEM VOL. 201, January 3, 2005 71
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All mice were genotyped by Southern blot analysis (51) and maintained un-
der pathogen-free conditions. Athymic NMRI nude mice (6–8 wk) were
obtained from The Jackson Laboratory. The animal experiments were ap-
proved from the Regional Board of Land Hessen, Germany.
Model of hind limb ischemia. The proximal femoral artery, including
the superficial and the deep branch as well as the distal saphenous artery,
were ligated. In transplantation experiments, progenitor cells were intrave-
nously injected in nude mice 24 h after induction of limb ischemia. Human
EPCs were pretreated with 20  g/ml activating  2-integrin antibody (clone
KIM 185) or isotype control antibody for 30 min at 37 C and washed twice
to remove unbound antibodies before injection (105 EPCs/mouse). In some
experiments, sex-mismatched murine Sca-1 /Lin  or Flk-1 /Lin  bone
marrow cells from male  2    or wild-type mice were used. After 2 wk, we
calculated the ischemic (right) versus normal (left) limb blood flow ratio us-
ing a Laser Doppler blood flow imager (Moor Instruments).
Histology.  The capillary density and the number and size of conductant
vessels in the semimembraneous and adductor muscles were determined us-
ing 8- m cryosections. Endothelial cells were identified with the panendo-
thelial marker MECA-32 followed by donkey anti–rat IgG Alexa488 or
CD31-FITC (BD Biosciences). Injected human EPCs were identified by
costaining for HLA-ABC (allophycocyanin labeled; BD Biosciences) and
vWF (Acris). Male murine BM-derived cells were identified by fluores-
cence in situ hybridization for the murine Y-chromosome (Cy3-labeled
probe: Cambio; reference 7). Nuclei were stained with Sytox (Molecular
Probes). Images were obtained by confocal microscopy (LSM 510; Carl
Zeiss MicroImaging, Inc.).
Statistical analysis
Continuous variables are expressed as mean   SD or SEM. Comparisons
between groups were analyzed by Student’s t test (two-sided) or analysis of
variance with Bonferroni adjustment for experiments with more than two
subgroups (SPSS 11.5 software). p-values  0.05 were considered as statisti-
cally significant.
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